IN8bio

IN8bio Dividend Coverage

Dividend Coverage Ratio of IN8bio (INAB) as of Oct 20, 2026.

Dividend Coverage

-

Last updated:

Dividend Coverage Ratio of IN8bio is 2026 - . Dividend Coverage Ratio of IN8bio was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IN8bio Stock analysis

What does IN8bio do? IN8bio Inc is a clinical-stage biopharmaceutical company based in New York City, operating in the Health Care sector within the Biotechnology industry. The company develops novel therapies using allogeneic, autologous, and genetically modified gamma-delta T cells for treating cancers, including solid tumors and hematologic malignancies. With 26 employees, it focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates, currently advancing Phase 1 and Phase 2 clinical trials for glioblastoma and other cancer treatments. IN8bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IN8bio stock

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio IN8bio since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's IN8bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — IN8bio

All Key Metrics — IN8bio